160 related articles for article (PubMed ID: 19519493)
1. Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors.
Díaz-González R; Pérez-Pertejo Y; Prada CF; Fernández-Rubio C; Balaña-Fouce R; Reguera RM
Mini Rev Med Chem; 2009 Jun; 9(6):674-86. PubMed ID: 19519493
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids.
Reguera RM; Díaz-González R; Pérez-Pertejo Y; Balaña-Fouce R
Curr Drug Targets; 2008 Nov; 9(11):966-78. PubMed ID: 18991609
[TBL] [Abstract][Full Text] [Related]
3. The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure.
Cavalcanti DP; Fragoso SP; Goldenberg S; de Souza W; Motta MC
Parasitol Res; 2004 Dec; 94(6):439-48. PubMed ID: 15517387
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.
García-Estrada C; Prada CF; Fernández-Rubio C; Rojo-Vázquez F; Balaña-Fouce R
Proc Biol Sci; 2010 Jun; 277(1689):1777-87. PubMed ID: 20200034
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.
Reguera RM; Redondo CM; Gutierrez de Prado R; Pérez-Pertejo Y; Balaña-Fouce R
Biochim Biophys Acta; 2006; 1759(3-4):117-31. PubMed ID: 16757380
[TBL] [Abstract][Full Text] [Related]
6. Targeting atypical trypanosomatid DNA topoisomerase I.
Balaña-Fouce R; Redondo CM; Pérez-Pertejo Y; Díaz-González R; Reguera RM
Drug Discov Today; 2006 Aug; 11(15-16):733-40. PubMed ID: 16846801
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerases in life and death: implications in kinetoplastid protozoa.
Chowdhury AR; Majumder HK
Curr Mol Med; 2004 Sep; 4(6):711-22. PubMed ID: 15357219
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases as targets for antiprotozoal therapy.
Bakshi RP; Shapiro TA
Mini Rev Med Chem; 2003 Sep; 3(6):597-608. PubMed ID: 12871162
[TBL] [Abstract][Full Text] [Related]
9. Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.
Balaña-Fouce R; Alvarez-Velilla R; Fernández-Prada C; García-Estrada C; Reguera RM
Int J Parasitol Drugs Drug Resist; 2014 Dec; 4(3):326-37. PubMed ID: 25516844
[TBL] [Abstract][Full Text] [Related]
10. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
11. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerases of kinetoplastid parasites: why so fascinating?
Das BB; Sengupta T; Ganguly A; Majumder HK
Mol Microbiol; 2006 Nov; 62(4):917-27. PubMed ID: 17042788
[TBL] [Abstract][Full Text] [Related]
13. Glyoxalase pathway of trypanosomatid parasites: a promising chemotherapeutic target.
Chauhan SC; Padmanabhan PK; Madhubala R
Curr Drug Targets; 2008 Nov; 9(11):957-65. PubMed ID: 18991608
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
16. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
17. [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].
Reguera RM; Pérez-Pertejo Y; Redondo CM; Díaz-González R; Balaña-Fouce R
Medicina (B Aires); 2007; 67(6 Pt 2):747-57. PubMed ID: 18422072
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of type II topoisomerase in the endosymbiont-bearing Trypanosomatid Blastocrithidia culicis.
Lourenço EE; Cavalcanti DP; Assine Picchi GF; Souza W; Aurélio Krieger M; Machado Motta MC; Goldenberg S; Perdigão Fragoso S
FEMS Microbiol Lett; 2006 Apr; 257(1):163-70. PubMed ID: 16553848
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
20. Iridoids as DNA topoisomerase I poisons.
Gálvez M; Martín-Cordero C; Ayuso MJ
J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
